Results 181 to 190 of about 10,368 (217)

Use of dupilumab in the management of refractory prurigo nodularis in an immunosuppressed double transplanted patient. [PDF]

An Bras Dermatol
Valenzuela Godoy D, Agüero R, Kolbach M.   +2 more
europepmc   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials. [PDF]

Dermatol Ther (Heidelb)
Stander S, Zeidler C, Msihid J, Makhija M, Bansal A, Wiggins S, Zahn J, Thomas RB, Bahloul D.   +8 more
europepmc   +1 more source

Delayed Inflammatory Reactions to Hyaluronic Acid Fillers in a Patient Undergoing Dupilumab Therapy: A Case Report

Journal of Cosmetic Dermatology, Volume 25, Issue 8, August 2026.
ABSTRACT Background Delayed inflammatory reactions to hyaluronic acid (HA) dermal fillers are uncommon but clinically significant, particularly in patients receiving immunomodulatory biologic therapies. Dupilumab, an interleukin‐4 receptor alpha (IL‐4Rα) inhibitor approved for chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 ...
Osamah Alkhuzaim, Abdullah Almeziny
wiley   +1 more source

Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study. [PDF]

Adv Ther
Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Kataoka Y, Blauvelt A, Wollenberg A, Eichenfield LF, Khokhar FA, Coleman A, Van Spall M, Ma Y, Avetisova E, Zhang A, Nguyen TV.   +15 more
europepmc   +1 more source

Dupilumab as a rescue therapy for steroid-dependent eosinophilic gastritis in a child unresponsive to elimination diet: a case report. [PDF]

Front Pediatr
Piccirillo M, Di Nardo G, Pilozzi E, Furio S, Di Marino VP, Pucinischi V, Dilaghi E, Parisi P, Ferretti A, Mennini M.   +9 more
europepmc   +1 more source

Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics. [PDF]

J Inflamm Res
Wang SH, Li SZ, Li YR, Zhang J, Wang Y, Zuo YG.   +5 more
europepmc   +1 more source

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. [PDF]

Front Med (Lausanne)
Didona D, Mariotti F, Pira A, Didona B, Hertl M, Di Zenzo G.   +5 more
europepmc   +1 more source

Factors Associated With Dupilumab Efficacy in Patients With Chronic Rhinosinusitis With Nasal Polyps. [PDF]

OTO Open
Takaishi S, Otori N.
europepmc   +1 more source

Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence. [PDF]

J Asthma Allergy
Suter P, Buetler VA, Graf N, Pavlov N.
europepmc   +1 more source